Email your doctor to beat gout: new trial tests remote care

NCT ID NCT04733079

Ongoing Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether regular email communication between gout patients and their doctors can help lower uric acid levels more effectively than standard care. 204 adults with confirmed gout will either follow usual care or use a secure messaging system to adjust their medication dose until their uric acid target is reached. The goal is to see if this remote, treat-to-target approach can improve gout control and reduce flares.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cleanweb electronic messaging ePro
What this could lead to: If successful, this could offer a simple, remote way to manage gout effectively, reducing flares and complications.
What could go wrong: This is a relatively small, early-stage trial comparing email follow-up to usual care. The approach may not work for everyone, and results may not apply to all gout patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout Hyperuricemia Patient Compliance rheumatic disorder rheumatic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GOUT HYPERURICEMIA INFLAMMATORY RHEUMATISM POSOLOGY ADJUSTMENT

Contacts and locations

Locations

Hopital LARIBOISIERE - Rhumatologie

Paris, 75010, France
Rhumathology department

Paris, Île-de-France Region, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.